BioCentury
ARTICLE | Clinical News

Custirsen sodium: Phase III discontinued

March 19, 2012 7:00 AM UTC

OncoGenex and partner Teva said they will conduct an international Phase III trial evaluating custirsen plus Jevtana cabazitaxel as second-line therapy in about 630 men with CRPC in lieu of the Phase III SATURN trial. The new trial will evaluate overall survival (OS) and begin next half. The partners said the change is due to "numerous, recently-approved agents that are redefining the standard of care in this patient setting." OncoGenex said it plans to begin closing down the double-blind, placebo-controlled, international SATURN trial this quarter. SATURN trial was enrolling about 300 men to evaluate durable pain palliation benefit of custirsen plus docetaxel/prednisone as second-line chemotherapy. ...